The reported association between use of zoledronic acid (Aclasta) and renal impairment
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]
Fosamax and atrial fibrillation: Osteoporosis Canada responds
We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]
Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]
A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]
